Home Companies Catalysts Deep Dives
Mayzent siponimod APPROVED
Drug Profile
ModalitySmall molecule
RouteOral
Therapy AreaNeurology
Launch2019-03-26
US LOE2030-03-26
Peak Sales Est$800M
Formulations[{"id":"mayzent-oral","doses":"0.25mg, 2mg tablets","route":"Oral","setting":"PATIENT_SELF","frequen
Companies
NVS (ORIGINATOR)100%
Mechanism: S1P receptor modulator
Expert: Selective sphingosine-1-phosphate receptor 1,5 modulator
Everyday: Traps immune cells in lymph nodes to reduce MS attacks
Targets: ["S1PR"]
Revenue History
PeriodRevenue ($M)
2024$420M
2025$380M
Programs (2)
IndicationStageKey StudyRegional Status
SPMSAPPROVEDEXPAND[{"stage":"APPROVED","region":"US","approval_date":"2019-03-26"},{"stage":"APPRO
RMSAPPROVEDEXPAND[{"stage":"APPROVED","region":"US","approval_date":"2019-03-26"}]
Notes
S1P modulator for MS. Oral alternative to injectables.
Data from Supabase · Updated 2026-03-24